Next Article in Journal
Evaluation of a Lyophilized CRISPR-Cas12 Assay for a Sensitive, Specific, and Rapid Detection of SARS-CoV-2
Next Article in Special Issue
The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2
Previous Article in Journal
Interactions of HIV-1 Capsid with Host Factors and Their Implications for Developing Novel Therapeutics
Previous Article in Special Issue
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment
Review

Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective

1
Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3N6, Canada
2
Scientific Research Division, Novateur Ventures Inc., Vancouver, BC V6E 3P3, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Kenneth Lundstrom
Viruses 2021, 13(3), 418; https://doi.org/10.3390/v13030418
Received: 11 February 2021 / Revised: 27 February 2021 / Accepted: 3 March 2021 / Published: 5 March 2021
(This article belongs to the Special Issue Vaccines and Therapeutics against Coronaviruses)
The coronavirus SARS-CoV-2, which causes Coronavirus disease 2019 (COVID-19), has infected more than 100 million people globally and caused over 2.5 million deaths in just over one year since its discovery in Wuhan, China in December 2019. The pandemic has evoked widespread collateral damage to societies and economies, and has destabilized mental health and well-being. Early in 2020, unprecedented efforts went into the development of vaccines that generate effective antibodies to the SARS-CoV-2 virus. Teams developing twelve candidate vaccines, based on four platforms (messenger RNA, non-replicating viral vector, protein/virus-like particle, and inactivated virus) had initiated or announced the Phase III clinical trial stage by early November 2020, with several having received emergency use authorization in less than a year. Vaccine rollout has proceeded around the globe. Previously, we and others had proposed a target product profile (TPP) for ideal/optimal and acceptable/minimal COVID-19 vaccines. How well do these candidate vaccines stack up to a harmonized TPP? Here, we perform a comparative analysis in several categories of these candidate vaccines based on the latest available trial data and highlight the early successes as well as the hurdles and barriers yet to be overcome for ending the global COVID-19 pandemic. View Full-Text
Keywords: COVID-19; SARS-CoV-2; vaccine; target product profile; immune response; coronavirus; clinical trial; public health COVID-19; SARS-CoV-2; vaccine; target product profile; immune response; coronavirus; clinical trial; public health
Show Figures

Figure 1

MDPI and ACS Style

Funk, C.D.; Laferrière, C.; Ardakani, A. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. Viruses 2021, 13, 418. https://doi.org/10.3390/v13030418

AMA Style

Funk CD, Laferrière C, Ardakani A. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. Viruses. 2021; 13(3):418. https://doi.org/10.3390/v13030418

Chicago/Turabian Style

Funk, Colin D., Craig Laferrière, and Ali Ardakani. 2021. "Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective" Viruses 13, no. 3: 418. https://doi.org/10.3390/v13030418

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop